Coffee consumption and risk of multiple sclerosis: A systematic review and meta-analysis

IF 9.2 1区医学 Q1 IMMUNOLOGY

Autoimmunity reviews Pub Date : 2025-04-24 DOI:10.1016/j.autrev.2025.103822

Mehrad Amirnia , Khazar Raeisnia , Hamidreza Ashayeri , Zahra Hakimzadeh , Ehsan Nasiri , Mahnaz Talebi , Sarvin Sanaie , Amirreza Naseri

{"title":"Coffee consumption and risk of multiple sclerosis: A systematic review and meta-analysis","authors":"Mehrad Amirnia , Khazar Raeisnia , Hamidreza Ashayeri , Zahra Hakimzadeh , Ehsan Nasiri , Mahnaz Talebi , Sarvin Sanaie , Amirreza Naseri","doi":"10.1016/j.autrev.2025.103822","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Multiple Sclerosis (MS) is an immune-mediated disease with miscellaneous etiological origins. Given caffeine's neuroprotective and anti-inflammatory attributes and its potential influence on MS risk, and to address the conflict in the clinical evidence, this study aims to comprehensively review the existing literature on the association between coffee consumption and the risk of MS.</div></div><div><h3>Methods</h3><div>Following the PRISMA 2020 guidelines, a systematic search in PubMed, Scopus, Web of Science, and Embase for the studies published up to January 2024 was conducted. Studies that assessed the relationship between coffee intake and the risk of MS were included, and reviews, case reports, non-English papers, in vitro and animal studies, and conference abstracts were excluded. The risk of bias was assessed using the JBI checklists, and meta-analyses were conducted based on odds ratio (OR) using the fourth version of CMA software.</div></div><div><h3>Results</h3><div>Out of 604 initial records, 10 observational studies with 19,430 participants met the inclusion criteria. The included case-control studies showed an overall high quality. Meta-analysis revealed a reduction in MS development in coffee consumers both before (OR: 0.66; 95 % CI: 0.49–0.90; <em>p</em>-value: 0.008; I<sup>2</sup>: 89.65 %; p-value for heterogeneity<0.001) and after adjustment for possible confounders (adjusted OR: 0.42; 95 % CI: 0.20–0.90; p-value: 0.025; I<sup>2</sup>: 89.65 l; p-value for heterogeneity<0.001).</div></div><div><h3>Conclusion</h3><div>Coffee consumption, may decrease the risk of MS; however, further well-designed prospective studies are required to ascertain this association.</div><div>PROSPERO registration number: CRD42023484298.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 7","pages":"Article 103822"},"PeriodicalIF":9.2000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmunity reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568997225000825","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Multiple Sclerosis (MS) is an immune-mediated disease with miscellaneous etiological origins. Given caffeine's neuroprotective and anti-inflammatory attributes and its potential influence on MS risk, and to address the conflict in the clinical evidence, this study aims to comprehensively review the existing literature on the association between coffee consumption and the risk of MS.

Methods

Following the PRISMA 2020 guidelines, a systematic search in PubMed, Scopus, Web of Science, and Embase for the studies published up to January 2024 was conducted. Studies that assessed the relationship between coffee intake and the risk of MS were included, and reviews, case reports, non-English papers, in vitro and animal studies, and conference abstracts were excluded. The risk of bias was assessed using the JBI checklists, and meta-analyses were conducted based on odds ratio (OR) using the fourth version of CMA software.

Results

Out of 604 initial records, 10 observational studies with 19,430 participants met the inclusion criteria. The included case-control studies showed an overall high quality. Meta-analysis revealed a reduction in MS development in coffee consumers both before (OR: 0.66; 95 % CI: 0.49–0.90; p-value: 0.008; I²: 89.65 %; p-value for heterogeneity<0.001) and after adjustment for possible confounders (adjusted OR: 0.42; 95 % CI: 0.20–0.90; p-value: 0.025; I²: 89.65 l; p-value for heterogeneity<0.001).

Conclusion

Coffee consumption, may decrease the risk of MS; however, further well-designed prospective studies are required to ascertain this association.

PROSPERO registration number: CRD42023484298.

查看原文本刊更多论文

咖啡消费与多发性硬化症的风险：一项系统回顾和荟萃分析

背景：多发性硬化症（MS）是一种病因复杂的免疫介导疾病。考虑到咖啡因的神经保护和抗炎特性及其对MS风险的潜在影响，并解决临床证据中的冲突，本研究旨在全面审查咖啡消费与MS风险之间关系的现有文献。方法根据PRISMA 2020指南，在PubMed， Scopus， Web of Science和Embase中系统检索截至2024年1月发表的研究。评估咖啡摄入量与多发性硬化症风险之间关系的研究被包括在内，综述、病例报告、非英文论文、体外和动物研究以及会议摘要被排除在外。使用JBI检查表评估偏倚风险，并使用第四版CMA软件基于比值比（OR）进行meta分析。结果604项初始记录中，10项观察性研究19430名受试者符合纳入标准。纳入的病例对照研究显示总体质量较高。荟萃分析显示，在喝咖啡之前，喝咖啡的人患多发性硬化症的几率都有所降低(OR: 0.66；95% ci: 0.49-0.90；假定值:0.008;I2: 89.65%；p值为异质性<；0.001)和校正后可能的混杂因素(校正OR: 0.42；95% ci: 0.20-0.90；假定值:0.025;I2: 89.65 l；p值表示异质性<；0.001)。结论咖啡饮用，可降低多发性硬化症的发病风险；然而，需要进一步精心设计的前瞻性研究来确定这种关联。普洛斯彼罗注册号：CRD42023484298。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Autoimmunity reviews 医学-免疫学

CiteScore

24.70

自引率

4.40%

发文量

164

审稿时长

21 days

期刊介绍： Autoimmunity Reviews is a publication that features up-to-date, structured reviews on various topics in the field of autoimmunity. These reviews are written by renowned experts and include demonstrative illustrations and tables. Each article will have a clear "take-home" message for readers. The selection of articles is primarily done by the Editors-in-Chief, based on recommendations from the international Editorial Board. The topics covered in the articles span all areas of autoimmunology, aiming to bridge the gap between basic and clinical sciences. In terms of content, the contributions in basic sciences delve into the pathophysiology and mechanisms of autoimmune disorders, as well as genomics and proteomics. On the other hand, clinical contributions focus on diseases related to autoimmunity, novel therapies, and clinical associations. Autoimmunity Reviews is internationally recognized, and its articles are indexed and abstracted in prestigious databases such as PubMed/Medline, Science Citation Index Expanded, Biosciences Information Services, and Chemical Abstracts.